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  Ninty of・ 134 patients with prostatic cancer received estrogen therapy from 1966・一st 1975 at Nagoya
University and Nagoya First Red Cross ffospital．
  Histologicai diagnosis was adenocarcinoma in all patients ： 4S O／． o’f’ 75 patients had differentiated
type and 540／， had poorly differentiated type．
  ’［［’wenty－three patients were classified in stage B， 35 in stage C and 32 in stage D．
  Patlents with elevated serum acid phosphatase were classified in stage D．
  Prolonged elevation of serum acid phosphatase indicated poor effect for relief of pain due to
adva4ced pr’ostatic cancer． Final relief of pain was obtained in 9 of 30 patients in stage D
  Estrogen therapy achieVed an objective response in 550／． of 86 patients witifi dysuria．
  Five－year relative survival rate of all phtients’ was 49．1±6．70／，． Stage B and Cl grbup shoxAvred
better survival rate than stage D and also differentiated type than pooly differentiated type．
  As for the ti．me o’f estrogen therapy， there was no significant difference of survival rate between
long time and short time in stage D and also stage B and C．・
  Twenty－nine of 52 patients followed over 5 years died from． prostatic carcinoma and 7 of the1ic｝一
（170／．） died from vascular disease．










 90例中stage B 23例， C 35例， D 32例であり，悪
性度を組織学的に診断できた75例ではGI・II46％，
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頃able 1． Five－year survival rate of patients with
    prostatic cancer on endocrine therapy．
No Acturlal Relative
Table 2． Causes of death from prostatic cancer by
   stage．
            Stage
D c B Totat
Stage
 B 25 55．5 71．2±13．8
 C 55 55．8 76．Oti，IO．7
 D 32 9．4 12．6±6．9
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t5 to 6 29
Duration of Medication （Stage B 8 C）Table 3．
Short 27 59．8 75．6±［2．5
Long 31 42．9 57．1±ll．8
aauses of death by adrninistration of DESP．
     Honvan
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Alive 7 ｛55 el．） 4 （15 0／e｝ 11 （2 1 “lo）
Totoi 21 51 52
多い傾向がみられた（Fig・3）・
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          する製剤である。グリチルリチンは，それ自体にコルチコステロイド
          作用を有するのみならず，コルチコイドの諸作用に対し，各個作用別
          に拮抗，増強する解離作用をもち，コルチコイド副作用の防止をも可
          能にする。最近，強ミノCは慢性肝炎に対し治効を有することが，
          重盲検法により，高い信頼度で立証された（医学のあゆみ，102巻，8号）。
     レグリチルリチン製剤
       夢艶力ネオミ／77』ゲγγ一
          包装 20rnl 5管・30管，5ml 5管・50管，2mt 10管・100管   健保略称
                                健保適用． 強ミノC
  ●適応症 肝炎，肝機能障害，胃潰瘍，十二指腸潰瘍，胃炎，
       ストロフルス，湿疹，皮膚炎，華麻疹，円形脱毛
       症，口内炎，薬物過敏症。
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